Drug Profile

Glucose responsive insulin - AmideBio

Alternative Names: AB-GSI-084

Latest Information Update: 23 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AmideBio
Class Antihyperglycaemics; Insulins; Pancreatic hormones
Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

22 Jan 2024 Glucose responsive insulin is still in preclinical trials for Type 1 diabetes mellitus and Type 2 diabetes mellitus in USA (AmideBio pipeline, January 2024)
16 May 2018 AB-GSI 084 is available for licensing as of 16 May 2018. http://www.amidebio.com/
16 May 2018 Preclinical trials in Type-1 diabetes mellitus in USA (unspecified route) before May 2018

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com